There remains an increased global demand for semaglutide products which is impacting availability and certainty of supply of Ozempic (semaglutide) in Australia until early 2023.
The TGA met with stakeholders including the AMA who co-developed a joint statement and discussed recommendations for patients and health professionals affected by the ongoing limited availability of Ozempic. Prescribers are advised to strongly consider alternatives where possible because of the current intermittent supply situation.
To prioritise essential continuity of care for people with type 2 diabetes during the shortage, health professionals should limit prescribing and dispensing of semaglutide to its approved use:
Treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:
as monotherapy when metformin is not tolerated or contraindicated
in addition to other medicinal products for the treatment of type 2 diabetes.
You can find further information here.
